Evidence map›Paper›PMID 38170217›Full record

ArticleActa neuropathologica2024

Disruption of MAM integrity in mutant FUS oligodendroglial progenitors from hiPSCs.

Yingli Zhu, Thibaut Burg, Katrien Neyrinck, Tim Vervliet, Fatemeharefeh Nami, Ellen Vervoort, Karan Ahuja, Maria Livia Sassano, Yoke Chin Chai, Arun Kumar Tharkeshwar and 8 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Altered Lipid Homeostasis in Mutant FUSMolecular neurobiology · 2025
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Yingli Zhu *Department of Development and Regeneration, Stem Cell Institute, KU Leuven, 3000, Leuven, Belgium. yingli.zhu@kuleuven.be.ORCID 0000-0002-8987-4673
Thibaut BurgDepartment of Neurosciences, Experimental Neurology, KU Leuven, Leuven Brain Institute (LBI), 3000, Leuven, Belgium.
Katrien Neyrinck *Department of Development and Regeneration, Stem Cell Institute, KU Leuven, 3000, Leuven, Belgium.
Tim VervlietLaboratory of Molecular and Cellular Signalling, Department of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.
Fatemeharefeh NamiDepartment of Development and Regeneration, Stem Cell Institute, KU Leuven, 3000, Leuven, Belgium.
Ellen VervoortLaboratory of Cell Death Research and Therapy, Department of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.
Karan AhujaDepartment of Development and Regeneration, Stem Cell Institute, KU Leuven, 3000, Leuven, Belgium.
Maria Livia SassanoLaboratory of Cell Death Research and Therapy, Department of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.
Yoke Chin ChaiDepartment of Development and Regeneration, Stem Cell Institute, KU Leuven, 3000, Leuven, Belgium.
Arun Kumar TharkeshwarDepartment of Neurosciences, Experimental Neurology, KU Leuven, Leuven Brain Institute (LBI), 3000, Leuven, Belgium.
Jonathan De SmedtDepartment of Development and Regeneration, Stem Cell Institute, KU Leuven, 3000, Leuven, Belgium.
Haibo HuNational Engineering Research Center for Modernization of Traditional Chinese Medicine-Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University, Ganzhou, China.
Geert BultynckLaboratory of Molecular and Cellular Signalling, Department of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.
Patrizia AgostinisLaboratory of Cell Death Research and Therapy, Department of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.
Johannes V SwinnenLaboratory of Lipid Metabolism and Cancer, Department of Oncology, KU Leuven, 3000, Leuven, Belgium.
Ludo Van Den BoschDepartment of Neurosciences, Experimental Neurology, KU Leuven, Leuven Brain Institute (LBI), 3000, Leuven, Belgium.
Rodrigo Furtado Madeiro da CostaDepartment of Development and Regeneration, Stem Cell Institute, KU Leuven, 3000, Leuven, Belgium.
Catherine VerfaillieDepartment of Development and Regeneration, Stem Cell Institute, KU Leuven, 3000, Leuven, Belgium.
KU Leuven · BEVIB-KU Leuven Center for Cancer Biology · BEVIB-KU Leuven Center for Brain & Disease Research · BEGannan Medical University · CNNeuroelectronics Research Flanders · BERega Institute for Medical Research · BE

Funding

China Scholarship Council 201908440360Fondation Thierry Latran ALS-OLFonds Wetenschappelijk Onderzoek 12AIK24NFonds Wetenschappelijk Onderzoek 12ZG121NFonds Wetenschappelijk Onderzoek SBO-S001221NFonds Wetenschappelijk Onderzoek W001422NGeneret Award for Rare Diseases IDN/22/012Research Council of the KU Leuven AKUL/19/34Research Council of the KU Leuven C14/19/099the ALS Liga ('A Cure for ALS') iBOF/23/02Universitaire Ziekenhuizen Leuven, KU Leuven C14-17-107Universitaire Ziekenhuizen Leuven, KU Leuven C14/22/132
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disorder, characterized by selective loss of motor neurons (MNs). A number of causative genetic mutations underlie the disease, including mutations in the fused in sarcoma (FUS) gene, which can lead to both juvenile and late-onset ALS. Although ALS results from MN death, there is evidence that dysfunctional glial cells, including oligodendroglia, contribute to neurodegeneration. Here, we used human induced pluripotent stem cells (hiPSCs) with a R521H or a P525L mutation in FUS and their isogenic controls to generate oligodendrocyte progenitor cells (OPCs) by inducing SOX10 expression from a TET-On SOX10 cassette. Mutant and control iPSCs differentiated efficiently into OPCs. RNA sequencing identified a myelin sheath-related phenotype in mutant OPCs. Lipidomic studies demonstrated defects in myelin-related lipids, with a reduction of glycerophospholipids in mutant OPCs. Interestingly, FUS

Indexed as

Amyotrophic Lateral SclerosisInduced Pluripotent Stem CellsDNA-Binding ProteinsHumansMotor NeuronsMutationOligodendrogliaRNA-Binding Protein FUSTranscription FactorsDNA-Binding ProteinsFUS protein, humanMAML1 protein, humanRNA-Binding Protein FUSTranscription FactorsAmyotrophic lateral sclerosisER stressFUSLipid defectsMAM disruptionMitochondrial dysfunction

Identifiers

PMID38170217
PMCPMC10764485
OpenAlexW4390539182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.